| The role of thrombospondin-1 in tumor progression I Sargiannidou, J Zhou, GP Tuszynski Experimental biology and medicine 226 (8), 726-733, 2001 | 162 | 2001 |
| Connexin32 mutations cause loss of function in Schwann cells and oligodendrocytes leading to PNS and CNS myelination defects I Sargiannidou, N Vavlitou, S Aristodemou, A Hadjisavvas, K Kyriacou, ... Journal of Neuroscience 29 (15), 4736-4749, 2009 | 140 | 2009 |
| Gap junction pathology in multiple sclerosis lesions and normal-appearing white matter K Markoullis, I Sargiannidou, N Schiza, A Hadjisavvas, F Roncaroli, ... Acta neuropathologica 123, 873-886, 2012 | 97 | 2012 |
| Disruption of oligodendrocyte gap junctions in experimental autoimmune encephalomyelitis K Markoullis, I Sargiannidou, C Gardner, A Hadjisavvas, R Reynolds, ... Glia 60 (7), 1053-1066, 2012 | 86 | 2012 |
| Axonal pathology precedes demyelination in a mouse model of X-linked demyelinating/type I Charcot-Marie Tooth neuropathy N Vavlitou, I Sargiannidou, K Markoullis, K Kyriacou, SS Scherer, ... Journal of Neuropathology & Experimental Neurology 69 (9), 945-958, 2010 | 86 | 2010 |
| Intrathecal gene therapy rescues a model of demyelinating peripheral neuropathy A Kagiava, I Sargiannidou, G Theophilidis, C Karaiskos, J Richter, ... Proceedings of the National Academy of Sciences 113 (17), E2421-E2429, 2016 | 83 | 2016 |
| Impairment of learning and memory in TAG-1 deficient mice associated with shorter CNS internodes and disrupted juxtaparanodes M Savvaki, T Panagiotaropoulos, A Stamatakis, I Sargiannidou, ... Molecular and Cellular Neuroscience 39 (3), 478-490, 2008 | 80 | 2008 |
| Oligodendrocyte gap junction loss and disconnection from reactive astrocytes in multiple sclerosis gray matter K Markoullis, I Sargiannidou, N Schiza, F Roncaroli, R Reynolds, ... Journal of Neuropathology & Experimental Neurology 73 (9), 865-879, 2014 | 66 | 2014 |
| Emerging therapies for Charcot-Marie-Tooth inherited neuropathies M Stavrou, I Sargiannidou, E Georgiou, A Kagiava, KA Kleopa International Journal of Molecular Sciences 22 (11), 6048, 2021 | 65 | 2021 |
| Gene replacement therapy in a model of Charcot-Marie-Tooth 4C neuropathy N Schiza, E Georgiou, A Kagiava, JJ Medard, J Richter, C Tryfonos, ... Brain 142 (5), 1227-1241, 2019 | 62 | 2019 |
| Connexins, gap junctions and peripheral neuropathy KA Kleopa, I Sargiannidou Neuroscience letters 596, 27-32, 2015 | 52 | 2015 |
| AAV9-mediated Schwann cell-targeted gene therapy rescues a model of demyelinating neuropathy A Kagiava, C Karaiskos, J Richter, C Tryfonos, MJ Jennings, ... Gene therapy 28 (10), 659-675, 2021 | 51 | 2021 |
| Gene therapy targeting oligodendrocytes provides therapeutic benefit in a leukodystrophy model E Georgiou, K Sidiropoulou, J Richter, C Papaneophytou, I Sargiannidou, ... Brain 140 (3), 599-616, 2017 | 51 | 2017 |
| Intraneural GJB1 gene delivery improves nerve pathology in a model of X‐linked Charcot–Marie–Tooth disease I Sargiannidou, A Kagiava, S Bashiardes, J Richter, C Christodoulou, ... Annals of neurology 78 (2), 303-316, 2015 | 49 | 2015 |
| Intrathecal gene therapy in mouse models expressing CMT1X mutations A Kagiava, C Karaiskos, J Richter, C Tryfonos, G Lapathitis, ... Human molecular genetics 27 (8), 1460-1473, 2018 | 46 | 2018 |
| Mechanisms of thrombospondin-1-mediated metastasis and angiogenesis I Sargiannidou, C Qiu, GP Tuszynski Seminars in thrombosis and hemostasis 30 (01), 127-136, 2004 | 44 | 2004 |
| Genetic mechanisms of peripheral nerve disease M Stavrou, I Sargiannidou, T Christofi, KA Kleopa neuroscience letters 742, 135357, 2021 | 43 | 2021 |
| Human oligodendrocytes express Cx31. 3: function and interactions with Cx32 mutants I Sargiannidou, M Ahn, AD Enriquez, A Peinado, R Reynolds, C Abrams, ... Neurobiology of disease 30 (2), 221-233, 2008 | 43 | 2008 |
| Systemic inflammation disrupts oligodendrocyte gap junctions and induces ER stress in a model of CNS manifestations of X-linked Charcot-Marie-Tooth disease M Olympiou, I Sargiannidou, K Markoullis, C Karaiskos, A Kagiava, ... Acta Neuropathologica Communications 4, 1-17, 2016 | 41 | 2016 |
| Gene replacement therapy after neuropathy onset provides therapeutic benefit in a model of CMT1X A Kagiava, J Richter, C Tryfonos, C Karaiskos, AJ Heslegrave, ... Human molecular genetics 28 (21), 3528-3542, 2019 | 37 | 2019 |
